Document:

Exhibit 10.1

 

Cooperation Agreement

on Transfer of Source
Plasma and Plasma Ingredients I+II+III Sediments 

for Producing Blood
Products

(Summary translation)

 

 

This Agreement is entered
into in the city of Beijing on September 30, 2014 by and between:

 

Party A (Supplier): Xinjiang
Deyuan Bioengineering Co., Ltd.

 

Party B (Receiver): Guizhou
Taibang Biological Products Co., Ltd.

 

WHEREAS:

 

1.  Both parties are
established in good standing under the laws of the People’s Republic of China (the “PRC”);

 

2.  Party A has certain
source plasma inventory for producing blood products (the “Source Plasma”) and plasma ingredients I+II+III sediments
(the “Ingredients”, which can be used to produce human immunoglobulin (PH4) for intravenous injection). Party
A has not obtained the drug registration number for producing human immunoglobulin (PH4), and the newly-built blood products workshop
has not been certified by 2010 GMP. Party A intends to provide the Source Plasma and the Ingredients which meet the regulatory
requirements to Party B for producing blood products. Both parties shall work together to obtain all the regulatory approvals from
the relevant governmental agencies, including without limitation, China Food and Drug Administration (the “Administration”).

 

NOW, THEREFORE, in consideration
of the premises set forth above, according to the relevant laws and regulations such as the Contract Law of the PRC and after adequate
and friendly negotiations, the Parties hereto agree as follows:

 

Section 1Subject
for Cooperation

 

The quality of Party
A’s Source Plasma and Ingredients shall be in compliance with the relevant requirements such as the Pharmacopoeia of the
PRC, the quality management regulations on plasma stations, the technical operational rules of plasma stations, the management
technical guidelines for the quarantine period of Source Plasma, and the relevant requirements for batch release management. The
actual amount of plasma transferred shall undergo final inspection by Party B and meet the production requirements.

 

Section 2Cooperation
Plan

 

1.  Both parties shall
make joint efforts to obtain all the relevant government approvals for transferring the Source Plasma and the Ingredients.

 

    	 

    	 

    

 

2.  After having obtained
approvals from the Administration (the “Administration Approval”), Party A shall provide Party B with the Source
Plasma and the Ingredients as approved by the Administration.

 

3.  If the quality
of the Source Plasma and the Ingredients meets the production requirements after inspection by Party B, both parties agree to settle
the payments at the following unit prices:

 

(1)  Unit price of
the Source Plasma (tax included) is RMB1.15 million/tonne

 

(2)  Unit price of
the Ingredients (tax included) is RMB500,000/tonne (plasma equivalent)

 

Section 3Delivery
and Transportation

 

1.  After having obtained
the Administration Approval, both parties shall negotiate the details of delivery within ten (10) business days, and determine
in writing, among other things, the content and timing of the initial inspection of goods, duration of transport, destination,
frequency of transport and conditions for transport.

 

2.  Party B shall
conduct the initial inspection for the Source Plasma and the Ingredients on the premises of Party A. If the Source Plasma and the
Ingredients meet the requirements after such inspection, Party A shall be responsible for transporting such Source Plasma and Ingredients
to the address of Party B in a condition suitable for transportation of the Source Plasma and the Ingredients. All the risks and
fees for transportation before the delivery of the above-mentioned goods to the address of Party B shall be borne by Party A.

 

Section 4Inspection

 

1.  Both parties agree
to conduct the inspection according to the application documents submitted to the Administration for obtaining the Source Plasma
and the Ingredients hereunder.

 

2.  After obtaining
the Administration Approval, Party B shall organize the quality auditing staff to conduct the audit at the enterprise and plasma
stations of Party A according to the auditing plan.

 

3.  Both parties confirm
that the inspection and acceptance of the Source Plasma relies on the information, plasma samples and active cooperation provided
by Party A. If the inspection and acceptance by Party B is in error due to the fault of Party A, the inspection and acceptance
by Party B shall not relieve Party A from the liabilities for quality defects of the Source Plasma, which shall be reported to
the competent local provincial government department. Party A shall be liable for any third-party damages, compensation claims
or administrative penalty resulting from the quality defects of the Source Plasma. Under such circumstances, if Party B makes payment
in advance, Party A shall indemnify and hold Party B harmless against all such payments.

 

4.  According to the
quality standard approved by the Administration, the inspection staff from both parties shall confirm the inspection method for
the Ingredients.

 

5.  Party B shall
inspect the Source Plasma and the Ingredients delivered to the site of Party B according to the inspection rules. If both parties
are in disagreement with the results of such inspection, they may apply for a qualified third-party inspection.

 

    	-2-

    	 

    

 

6.  Both parties confirm
that Party A shall be liable for all financial losses incurred by Party B due to prohibition by the relevant regulatory agencies
on production, batch-approval or sales as a result of the incompliance by Party A during its collection of the Source Plasma and
the Ingredients.

 

Section 5Deposit
and Payment Method

 

1.  Deposit

 

Within two (2) business
days after signing this Agreement, Party B shall pay RMB10 million as the deposit to the joint account established by Party A (the
“Joint Account”).

 

2.  Payment Method

 

(1)  After inspection
and acceptance by Party B of the Source Plasma and the Ingredients on the premises of Party A, Party B shall transfer to the Joint
Account the payment in an amount calculated based on RMB700,000/tonne for the Source Plasma and RMB500,000/tonne (plasma equivalent)
for the Ingredients minus the deposit of RMB10 million (the “Payment”).

 

(2)  After delivery
by Party A to the address of Party B and acceptance after inspection by Party B of the Source Plasma and the Ingredients, Party
B shall wire the Payment from the Joint Account to another account of Party A.

 

(3)  Party B shall
pay the shortfall of RMB450,000/tonne (calculated as the between the unit price of Source Plasma of RMB1.15 million/tonne and the
actually paid price of RMB700,000/tonne) based on the actually approved quantity to a bank account designated by Party A within
ten (10) business days after obtaining the batch-approval for a certain batch of finished products.

 

(4)  Party B shall
put to production the Source Plasma that meets its production requirements on a priority basis and covenant to complete such productions
and obtain the batch-approval for the finished products by June 30, 2015. Unless the failure to obtain the batch-approval is due
to the fault of Party A, if Party B fails to complete the production and obtain the batch-approval for the finished products by
June 30, 2015, Party B shall pay to Party A by July 10, 2015 the remaining balance for the Source Plasma that meets production
requirements.

 

Section 6Liabilities

 

1.  If any party breaches
this Agreement, the non-breaching party shall have the right to request the breaching party to specifically perform its obligations
under this Agreement and the breaching party shall be liable for all the loss incurred.

 

2.  Following the
Administration Approval, if Party A refuses or delays to perform this Agreement and fails to rectify within seven (7) days upon
written notice by Party B, Party A shall pay Party B an amount equal to the deposit multiplied by two and Party B shall be entitled
to terminate this Agreement by serving a written notice.

 

    	-3-

    	 

    

 

3.  Party A may retain
the deposit paid by Party B if Party B refuses to accept the Source Plasma and the Ingredients transferred by Party A without any
justifiable causes and fails to rectify within seven (7) days upon written notice by Party A.

 

Section 7Miscellaneous

 

1.  In addition to
other requisite governmental approvals, this Agreement shall be effective only upon the satisfaction of the following conditions:

 

(1)  The transfer
of the Source Plasmas and the Ingredients shall be approved by the Administration; and

 

(2)  The Administration
Approval for the transfer of the Source Plasma between Party A and Party B shall be obtained before October 31, 2014.

 

2.  If the Administration
Approval has not been obtained before October 31, 2014, except by mutual agreement to extend this Agreement, Party A shall repay
the deposit to the account of Party B before November 5, 2014, and this Agreement shall terminate accordingly. If Party A delays
such repayment, Party A shall pay a penalty in the amount of 0.3% of the overdue amount accrued on a daily basis.

 

3.  All disputes in
relation to this Agreement shall be governed by PRC laws. Both parties shall settle disputes through friendly negotiations. If
any dispute cannot be settled within thirty (30) days through friendly negotiations, either party shall submit the lawsuit to the
People’s court in plaintiff’s jurisdiction.

 

Section 8This
Agreement is made in four counterparts, and each party holds two. Each counterpart has the same legal effect.

 

 

Party A: Xinjiang Deyuan
Bioengineering Co., Ltd. (Seal)

 

Legal Representative
or Authorized Representative (Signature): /s/ Lv Xianzhong

 

 

Party B: Guizhou Taibang
Biological Products Co., Ltd. (Seal)

 

Legal Representative
or Authorized Representative (Signature): /s/ Yang Gang

 

September 30, 2014

 

    	-4-Exhibit 10.2

 

Supplemental Agreement
to Cooperation Agreement 

on Transfer of Source
Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products

(Summary translation)

 

 

This Supplemental Agreement
is entered into on April 16, 2015 by and between:

 

Party A (Supplier): Xinjiang
Deyuan Bioengineering Co., Ltd;

 

Party B (Receiver): Guizhou
Taibang Biological Products Co., Ltd

 

Any term not otherwise
defined herein shall have the meaning ascribed to it under the Original Agreement (as defined below).

 

Both parties entered
into the Cooperation Agreement on Transfer of Source Plasma and Plasma Ingredients I+II+III Sediments for Producing Blood Products
(the “Original Agreement”) on September 30, 2014. The Original Agreement provides that “[i]f the Administration
Approval has not been obtained before October 31, 2014, except by mutual agreement to extend [the Original] Agreement, Party A
shall repay the deposit to the account of Party B before November 5, 2014, and [the Original] Agreement shall terminate accordingly.
If Party A delays such repayment, Party A shall pay a penalty in the amount of 0.3% of the overdue amount accrued on a daily basis.”
The parties had not obtained the Administration Approval by October 31, 2014 and expected it difficult to obtain such approval
in near term. Since the Administration has accepted the application for the transfer of the Source Plasma under the Original Agreement,
following negotiations between the parties to facilitate their cooperation under the Original Agreement, both parties agree to
amend the Original Agreement by entering into this Supplemental Agreement as follows:

 

1.  Section 5.2(4) of
the Original Agreement shall be amended and replaced by the following in its entirety: “Party B shall put to production the
Source Plasma that meets its production requirements on a priority basis and covenant to complete such productions and obtain the
batch-approval for the finished products by November 30, 2015. Unless the failure to obtain the batch-approval is due to the fault
of Party A, if Party B fails to complete the production and obtain the batch-approval for the finished products by November 30,
2015, Party B shall pay to Party A by December 10, 2015 the remaining balance for the Source Plasma that meets production requirements.”

 

2.  Section 7.1(2)
of the Original Agreement shall be amended and replaced by the following in its entirety: “The Administration Approval for
the transfer of the Source Plasma between Party A and Party B shall be obtained before April 5, 2015.”

 

3.  Section 7.2 of
the Original Agreement shall be amended and replaced by the following in its entirety: “If the Administration Approval has
not been obtained before April 5, 2015, except by mutual agreement to extend this Agreement, Party A shall repay the deposit to
the account of Party B before April 10, 2015, and this Agreement shall terminate accordingly. If Party A delays such repayment,
Party A shall pay a penalty in the amount of 0.3% of the overdue amount accrued on a daily basis.”

 

4.  This Supplemental
Agreement shall be effective upon the signature and seal by both parties.

 

    	 

    	 

    

 

5.  The Original Agreement
shall remain effective to the extent not amended and superseded by this Supplemental Agreement.

 

6.  This Supplemental
Agreement shall be made in four counterparts, and each party holds two. Each counterpart shall have the same legal effect.

 

 

Party A: Xinjiang Deyuan
Bioengineering Co., Ltd (Seal)

 

Legal Representative
or Authorized Representative (Signature): /s/ Lv Xianzhong

 

 

Party B: Guizhou Taibang
Biological Products Co., Ltd (Seal)

 

Legal Representative
or Authorized Representative (Signature): /s/ Yang Gang

 

April 16, 2015

 

    	-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]